What is 3Derm?
3Derm is at the forefront of dermatological innovation, offering advanced skin imaging technology and comprehensive teledermatology services. The company's proprietary system captures high-quality images essential for accurate patient triage and diagnosis. Leveraging world-class algorithms, 3Derm provides healthcare providers with tools for precise skin disease identification. The recent FDA Breakthrough Device designations for its autonomous skin cancer AI highlight the company's commitment to pioneering solutions that enhance dermatological care and patient outcomes. This focus on cutting-edge technology positions 3Derm as a key player in the digital health and medical imaging sectors.
How much funding has 3Derm raised?
3Derm has raised a total of $2.8M across 2 funding rounds:
Private Equity
$1.2M
Private Equity
$1.7M
Private Equity (2014): $1.2M, investors not publicly disclosed
Private Equity (2016): $1.7M, investors not publicly disclosed
What's next for 3Derm?
With the recent major strategic investment, 3Derm is poised for significant expansion and technological advancement. The company's enterprise-level funding suggests a mature stage of development, likely focused on scaling operations, broadening market reach, and further developing its AI-driven diagnostic capabilities. This capital will be instrumental in commercializing its FDA-designated technologies and enhancing its teledermatology platform. Strategic partnerships and continued innovation in AI for skin cancer detection are anticipated as 3Derm aims to revolutionize dermatological diagnostics and treatment accessibility.
See full 3Derm company page
